Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion
NASDAQ:DRTS

Alpha Tau Medical Q3 2026 Earnings Date & Estimates

Alpha Tau Medical logo
$13.16 +0.26 (+2.02%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$13.05 -0.11 (-0.82%)
As of 10/23/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alpha Tau Medical is estimated to report Q3 2026 earnings on Thursday, November 19, 2026, before market opens. The conference call is scheduled for November 17, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Alpha Tau Medical in Q3 2026

Alpha Tau Medical is expected to post earnings of -$0.14 per share on revenue of $0.24 million. In the same quarter a year earlier Alpha Tau Medical reported -$0.14 per share. Alpha Tau Medical last reported on August 10, 2026, posting -$0.50 per share and missing the -$0.1409 consensus estimate. Alpha Tau Medical has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.14
Expected Revenue
$0.24 million
Prior-Year EPS
-$0.14

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.50 (Missed by -$0.3591)
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

Alpha Tau Medical Q3 2026 Earnings FAQ

Alpha Tau Medical (NASDAQ:DRTS) is estimated to report Q3 2026 earnings on Thursday, November 19, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Alpha Tau Medical's Q3 2026 earnings conference call is scheduled for Tuesday, November 17, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Alpha Tau Medical to post earnings of -$0.14 per share for Q3 2026.

The consensus revenue estimate for Alpha Tau Medical is $0.24 million for Q3 2026.

Alpha Tau Medical Earnings Headlines

Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea
October 22 at 9:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/22/3386354/0/en/alpha-tau-and-samsung-medical-center-sign-mou-to-explore-clinical-trial-of-alpha-dart-for-pancreatic-cancer-patients-in-korea.html
Alpha Tau Medical (NASDAQ:DRTS) Earns "Buy" Rating from HC Wainwright
October 22 at 2:18 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31145101
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.tc pixel
October 25 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Alpha Tau Medical Gets FDA Approval to Expand Brain Cancer Trial
October 19, 2026  |  marketscreener.comM
Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting
October 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/19/3383438/0/en/alpha-tau-announces-fda-approval-to-expand-alpha-dart-u-s-recurrent-glioblastoma-regain-trial-new-trial-data-to-be-presented-at-sno-2026-annual-meeting.html
Alpha Tau Medical (DRTS) dominates Reddit with 267 comments on Oct. 5
October 5, 2026  |  247wallst.comhttps://247wallst.com/cards/alpha-tau-medical-is-swallowing-the-board-with-267-comments-drts-reddit-radar-01m464f4v5kqvkj9ywycjcg3px
See More Alpha Tau Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alpha Tau Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alpha Tau Medical and other key companies, straight to your email.

About Alpha Tau Medical

Alpha Tau Medical (NASDAQ:DRTS) is an Israel-based medical technology company developing targeted radiation treatments for solid tumors. Its lead technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), is designed to deliver highly localized alpha radiation directly within a tumor while limiting exposure to surrounding healthy tissue.

Alpha DaRT uses tiny radioactive sources, including radium-224, that are placed in or near a tumor. The sources generate short-range alpha-emitting atoms that diffuse through the tumor and damage cancer cells. The company has studied the technology in several solid-tumor settings and is advancing it through clinical development for potential use in cancers that may be difficult to treat with conventional approaches.

Founded in Israel, Alpha Tau conducts research and clinical-development activities in Israel and other international markets, including the United States and Europe. Alpha DaRT remains an investigational technology, and its availability and use depend on regulatory authorization in each jurisdiction.

View Alpha Tau Medical Profile
Earnings Tools